Clearmind Medicine Inc. (CMND) Form 6-K — Sep 2, 2026
Clearmind Medicine entered into a conversion agreement dated September 2, 2026 with its two CLA Investors, under which an aggregate of $687,500 of convertible promissory notes — $696,079.50 including accrued interest — was converted into common shares at an agreed price of $1.00 per share. The notes were issued under securities purchase agreements dated September 17, 2025 and amended April 30, 2026, which permit the company to issue and sell up to $10,000,000 of convertible notes. The parties also amended the floor price in the form of Promissory Note to $1.00 per common share.
Key figures
- Debt Amount
- 10000000
- Amended Floor Price
- $1.00 per common share
- Converted Principal
- 687500
- Agreed Conversion Price
- $1.00 per common share
- Notes Facility Capacity
- up to $10,000,000 of convertible promissory notes under the SPAs
- Implied Conversion Shares
- approximately 696,080 common shares (calculated: $696,079.50 / $1.00 per share; not explicitly stated in the filing)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.